ASM Microbe

ASM Microbe

June 30, 2016
2 min watch
Save

VIDEO: TAF-based regimen demonstrates safety, efficacy in patients with diabetes, renal impairment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The fixed-dose combination tablet of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) demonstrated “encouraging” results in a post-hoc analysis of patients with HIV and renal impairment, some of whom had diabetes, according to David K. Stein, MD, of Albert Einstein College of Medicine and Jacobi Medical Center, both in the Bronx, NY.

The investigation by Stein and colleagues looked specifically at markers of renal function, including proteinuria. These markers declined in patients with and without diabetes, which may indicate that E/C/F/TAF is “a safer alternative” for patients with HIV, diabetes and renal impairment.

“As clinicians, we’re always in a balancing act where we want something that’s highly efficacious, but we really don’t want to hurt patients,” Stein said. “This [agent] is raising the bar on efficacy and lowering the likelihood of toxicity.”